What is the current stock price of AbCellera Biologics Inc. (ABCL)?

As of the latest market data, AbCellera Biologics Inc. (ABCL) is trading at $5.44. The stock has seen a gain of 2.84% today.

Does AbCellera Biologics Inc. (ABCL) pay a dividend?

Based on current data, AbCellera Biologics Inc. does not have a confirmed active dividend policy.

What is the market cap of AbCellera Biologics Inc.?

The current market capitalization of AbCellera Biologics Inc. (ABCL) is approximately unavailable.

ABCL

AbCellera Biologics Inc.·Healthcare

5.44

2.836%(+0.15)

Close Price

Last Updated: — ET

52W L: $1.9852W H: $6.51

ABCL NEWS

zacks.com

5d ago

Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

247wallst.com

May 18

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.

zacks.com

May 14

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

seekingalpha.com

May 14

AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com

May 12

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

marketbeat.com

May 11

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years.

Company Profile

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

596

IPO Date

2020-12-11

Beta

1.03

Websitewww.abcellera.com↗